NR4A1 and breast carcinoma: Inhibitors of PI3Kα, most notably alpelisib, have transformed the management of hormone receptor–positive, HER2-negative, PIK3CA-mutated advanced breast cancer, but their use is frequently limited by treatment-emergent hyperglycemia.